374Water And 2 Other Promising US Penny Stocks To Watch

In This Article:

As the U.S. stock market experiences a pullback from record highs, with major indices like the Dow Jones and S&P 500 seeing declines, investors are closely watching economic indicators and corporate earnings reports for signs of future trends. In such a fluctuating environment, penny stocks—often representing smaller or newer companies—can present intriguing opportunities for those willing to look beyond established names. Despite being considered somewhat outdated as a term, these stocks continue to attract attention due to their potential for growth and value.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7987

$5.8M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$2.95

$485.02M

★★★★★★

RLX Technology (NYSE:RLX)

$1.65

$2.1B

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.42

$147.91M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.595

$52.63M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$3.76

$114.05M

★★★★★★

MIND C.T.I (NasdaqGM:MNDO)

$1.88

$39.56M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.07

$96.23M

★★★★★☆

Click here to see the full list of 749 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

374Water

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: 374Water Inc. operates in the United States, offering technology that converts wet wastes into recoverable resources, with a market cap of $229.62 million.

Operations: The company's revenue segment is entirely derived from the United States, totaling $0.24 million.

Market Cap: $229.62M

374Water Inc., with a market cap of US$229.62 million, operates in the waste-to-resource technology sector but remains pre-revenue, generating only US$0.24 million annually. The company is debt-free and has short-term assets of US$8.8 million exceeding liabilities, yet it faces a cash runway of less than a year due to negative free cash flow trends. Recent activities include filing for a US$30.73 million shelf registration and appointing Peter Mandel as General Counsel to aid in scaling operations and commercialization efforts amid ongoing losses and revenue decline from previous years.

NasdaqCM:SCWO Debt to Equity History and Analysis as at Oct 2024
NasdaqCM:SCWO Debt to Equity History and Analysis as at Oct 2024

Atai Life Sciences

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing and investing in therapeutics for mental health disorders such as depression, anxiety, and addiction, with a market cap of approximately $214.78 million.